{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8606","upperLimit":"0.9743","value":"0.9394"},{"groupId":"OG001","lowerLimit":"0.9671","upperLimit":"0.9993","value":"0.9953"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"235"}],"units":"Participants"}],"description":"EFS distributions will be estimated by the Kaplan-Meier method for patients with high risk features according to central review and treated with adjuvant chemotherapy and separately for subjects with central review recommendation of enucleation alone.","dispersionType":"95% Confidence Interval","groups":[{"description":"Includes patients who may or may not require chemotherapy. Patients who require chemotherapy receive vincristine IV and carboplatin IV over 1 hour on day 1 and etoposide IV over 1 hour on days 1 and 2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity and patients who complete chemotherapy are followed after completion of therapy periodically for at least 5 years. Patients who do not require chemotherapy undergo observation periodically for at least 5 years.","id":"OG000","title":"Group 1 (Identified by Central Review as High Risk)"},{"description":"Patients undergo observation periodically for at least 5 years.","id":"OG001","title":"Group 2 (Identified by Central Review as Not High Risk)"}],"paramType":"NUMBER","populationDescription":"Only eligible patients are considered in the characterization of EFS at 2 years.","reportingStatus":"POSTED","timeFrame":"At 2 years","title":"Event-free Survival (EFS)","type":"PRIMARY","unitOfMeasure":"Estimated Probability"}